1 Antiretroviral therapy (ART) for HIV-1 infection is life-long. Stopping therapy typically leads to the 2 reignition of infection and progressive disease. In a major breakthrough, recent studies have shown 3 that early initiation of ART can lead to sustained post-treatment control of viremia, raising hopes 4 of long-term HIV-1 remission. ART, however, elicits post-treatment control in a small fraction of in-5 dividuals treated. Strikingly, passive immunization with broadly neutralizing antibodies (bNAbs) of 6 HIV-1 early in infection was found recently to elicit long-term control in a majority of SHIV-infected 7 macaques, suggesting that HIV-1 remission may be more widely achievable. The mechanisms under-8 lying the control elicited by bNAb therapy, however, remain unclear. Untreated infection typically 9 leads to progressive disease. We hypothesized that viremic control represents an alternative but rarely 10 realized outcome of the infection and that early bNAb therapy triggers a dynamical switch to this 11 outcome. To test this hypothesis, we constructed a model of viral dynamics with bNAb therapy and 12 applied it to analyse clinical data. The model fit quantitatively the complex longitudinal viral load data 13 from macaques that achieved lasting control. The model predicted, consistently with our hypothesis, 14 that the underlying system exhibited bistability, indicating two potential outcomes of infection. The 15 first had high viremia, weak cytotoxic effector responses, and high effector exhaustion, marking pro-16 gressive disease. The second had low viremia, strong effector responses, and low effector exhaustion, 17 indicating lasting viremic control. Further, model predictions suggest that early bNAb therapy elicited 18 lasting control via pleiotropic effects. bNAb therapy lowers viremia, which would also limit immune 19 exhaustion. Simultaneously, it can improve effector stimulation via cross-presentation. Consequently, 20 viremia may resurge post-therapy, but would encounter a primed effector population and eventu-21 ally get controlled. ART suppresses viremia but does not enhance effector stimulation, explaining its 22 limited ability to elicit post-treatment control relative to bNAb therapy. 23 2 Author Summary 24
Steady state analysis of the model indicates two outcomes of the infection: chronic infection with high viremia that marks progressive disease (red filled square), typically realized in the absence of treatment, and viremic control (blue filled square), a switch to which is orchestrated by early bNAb therapy. 87 To test whether the model accurately captured the underlying dynamics of infection and the influence 88 of bNAbs, we applied it to describe the viral load changes reported in Nishimura et al. 10 where 3 89 weekly infusions of a combination of two HIV-1 bNAbs, 3BNC117 and 10-1074, starting from day 3 Model fits (blue lines) to viral load data10 (symbols) from the 10 controller macaques, shown in individual panels. Empty symbols mark measurements showing undetectable viremia and filled symbols above detection. The latter were used for fitting and the former censored. Black dashed lines in all panels indicate the viral load detection limit (100 RNA copies/mL). The corresponding bNAb concentration dynamics are in Figure 3 . In all panels, phase I (yellow) marks the duration when bNAbs are present in circulation, phase II (green) the viremic resurgence post the clearance of bNAbs, phase III (blue) the ensuing viremic control, and, where relevant, phase IV (pink), in two parts, the disruption of this control using anti-CD8α and anti-CD8β Abs, respectively. For the macaque MVJ, we demonstrate the loss of viral control that occurs when effector depletion levels are increased (magenta line), as is observed with the macaque DFIK. The digitized data used for the fitting is available as a supplementary excel file (Database.xlsx). In all cases, predictions without bNAb therapy are included for comparison (red lines) . Parameter values used are in Tables 1 and S1. Macaques DEWP, MVJ, DFFX, DFKX, and DFIK were inoculated intrarectally and DEWL and MAF intravenously with 1000 TCID50 (50% tissue culture infective dose) of SHIVAD8-EO virus. DEMR, DEBA, and DEHW received 100 TCID 50 intravenously. Table S2 . 120 We hypothesized, based on the two outcomes, progressive disease vs. viremic control, achieved fol-121 lowing bNAb therapy as well as CD8 depletion, that lasting control observed with early bNAb therapy 122 was a distinct steady state of the system. This hypothesis of bistability, or the existence of two distinct 123 stable steady states, is consistent with a previous analysis of post-treatment control with ART 18 and 124 may be a general feature of the interactions between antigen and effector cells 20 . Indeed, solving our 125 model equations (Methods), we identified two underlying stable steady states ( Figure 5 ). The first Figure S1 .
Model predictions fit in vivo data

Viremic control is a distinct outcome of infection
Early, short-term bNAb therapy switches the outcome to viremic control via pleiotropic effects 135 When a new infection occurs, viremia rises significantly during the acute infection phase and achieves 136 high levels typically before an adaptive effector response is mounted. 36 The effector response thus 137 lags and is dominated by the virus. If left untreated, the high viremic state, leading to progressive 138 disease, is realized, as observed with untreated macaques challenged with SHIV 37,38 . Our model Tables 1  and S1 ). The corresponding dynamics of (c,d) the effector response and (e,f) the level of effector exhaustion. The phases are color coded as in Figure 2 . Red lines in all panels indicate model predictions with the same parameter values but in the absence of bNAb therapy. Our model predicts thus that bNAb therapy switches disease dynamics from reaching the high viremic, disease progressive state to the state of viremic control. Black dashed lines in (a,b) indicate the viral load detection limit (100 RNA copies/mL).
Our model also predicts that early bNAb therapy drove the infection to the state of lasting viremic 143 control (blue lines in Figure 6 ), in agreement with the observations in Nishimura et al. 10 . Further, our acute infection, bNAbs suppressed the viremic peak by enhancing viral clearance. The lower viremia would limit effector exhaustion. Further, bNAbs would increase antigen presentation and effector 147 stimulation. When the level of the administered bNAbs in circulation is diminished, viremia would 148 resurge but in the presence of a primed effector pool, which would be larger and/or less severely 149 exhausted than in untreated macaques (Figure 6c ance did not fit the data well ( Figure S2 ), whereas neglecting bNAb-induced upregulation of antigen 172 presentation yielded fits with a higher value of the Akaike information criterion (AIC) ( Figure S3 ).
Our analysis suggests, thus, that the rapid clearance of the virus, which lowered viremia and reversed effector exhaustion, together with increased antigen uptake, which led to enhanced effector stimula-175 tion, resulted in the lasting control of viremia elicited by early, short-term bNAb therapy. 0)). All other parameters are the same as those that yield the best-fit to the macaque DEHW (Table S1 ). Tables 1 and S1 . Efficacy of ART is assumed to be ε = 0.8.) The duration of ART is shown as a grey region. The black dashed lines in (a) indicates the viral load detection limit (100 RNA copies/mL).
bNAbs have an advantage over ART
Discussion
191
The recent success of passive immunization with bNAbs in eliciting functional cure of HIV-1 infection 192 can potentially revolutionize HIV-1 care. [10] [11] [12] [13] [14] [15] [16] [17] In this study, using mathematical modelling and analysis gp120 Abs in controllers, we ignored the ability of bNAbs to upregulate the humoral response 49, 50 .
234
Our study is thus conservative in its assessment of the influence of bNAbs. We did not consider data AIDS using a single model has been a long-standing challenge. 51 One possibility for the failure of 238 bNAb therapy in the non-responders is that the bNAb therapy induced rapid viral load decline, limit-239 ing effector stimulation, and thus behaved like ART in the non-responders. 10 Alternatively, the non-240 responders may have had parameter settings that did not admit bistability, a possibility also with those 241 who failed to achieve post-ART control 18 . Note that the determinants of post-ART control are yet to be 242 established. 8, 9 Finally, we did not consider viral evolution and resistance to bNAbs, recognizing that 243 most controllers in Nishimura et al. 10 saw no resistance. Future studies with other combinations of 244 bNAbs may determine whether resistance must be accounted for in defining optimal bNAb treatments, 245 especially for use during chronic infection where viral diversity is likely to be large 52 .
246
In summary, our study presents the first quantitative description of viral dynamics following passive 
Methods
251
Model equations 252 We constructed the following equations to describe the viral dynamics depicted schematically in Figure   253 1.
Here, uninfected target CD4 + T cells, T , are produced at the rate λ T , die at the per capita rate d T , as the time to find interacting partners, the duration of each interaction, and cytokine/chemokine sig-287 nalling. 59, [61] [62] [63] Saturating forms are argued to be more realistic than mass-action forms 62 and follow 288 from kinetic considerations of these interactions under the total quasi-steady state approximation 63 .
289
Following activation, effectors such as CTLs and NK cells enter a proliferation program that does not 290 require antigen but can be modulated by antigen, cytokines and other stimulatory and co-stimulatory 291 signals. 59,64-67 Accordingly, we let effectors proliferate 68 with the rate constant k E , and, for simplicity, 292 subject to the same saturating dependence on antigen as activation. Effectors suffer exhaustion 19, 69 at the maximal rate ξ , with the half-maximal parameter q c and Hill coefficient n. The level of exhaus-294 tion, Q, increases with antigen level at the maximal rate κ and with the half-maximal parameter φ 2 .
295
Exhaustion is reversed with the rate constant d q . effectors are lost at the per capita rate d E . We note 296 that E is a measure of the effective effector pool, consisting of activated NK cells and SHIV-specific 297 CTLs, and factoring in the overall level of exhaustion, Q. E is thus not to be viewed as a cell count. of HIV 18 , also shows bistability but could not fit the present data with bNAb therapy ( Figure S4 and 301   Table S5 ). Similarly, variants of our model without the Hill coefficient, i.e., n=1 18 ( Figure S5 and Ta-302 ble S6), and with a Hill coefficient of n=3 19 ( Figure S6 and Table S7 ), or without an explicit effector 303 response ( Figure S7 and Table S8 ) could not fit the data. We also fit the viral load data by letting k E 304 vary. The model fits ( Figure S8 and Table S9 ) were comparable to the main model ( Figure 2 ) but with 305 higher AIC (Table 3) .
306
To mimic the dosing protocol in Nishimura et al. 10 , we let the serum concentration levels of the 307 bNAbs, A 1 and A 2 , rise by the extent A dose 1 /Vol 1 and A dose 2 /Vol 2 , immediately upon the administration 308 of a bNAb dose, and decline exponentially with the rate constants η 1 and η 2 , respectively. Here,
309
A dose 1 and A dose 2 correspond to the dosages of the two bnAbs, and Vol 1 and Vol 2 correspond to the 310 bNAb-specific volumes of distribution. The three doses were administered on days τ 1 = 3, τ 2 = 7, and 311 τ 3 = 10, respectively. Additionally, we allowed a delay in bNAb action, ω 1 and ω 2 , following each 312 dose, to account for any pharmacological effects within individual macaques. The Heaviside function, 313 H(t < (τ i + ω j )) = 0 and H(t ≥ (τ i + ω j )) = 1, accounts for bNAb dynamics based on these dosing times.
314
The maximal efficacies of the respective bNAbs, achieved when they are in excess, are set to k 1 and 315 k 2 , respectively, and their half-maximal efficacy is defined the Hill function threshold K. To compare 316 the influence of bNAbs with that of ART, we assumed that ART reduces β by a factor 1 − ε, where ε is 317 the efficacy of the drug combination 18 .
318
Long after bNAbs were cleared from circulation, Nishimura et al. 10 administered anti-CD8α an-319 tibodies to some macaques, which resulted in the depletion of effectors such as CD8 + T, NK, NKT, 320 and γδ T cells. Nishimura et al. 10 also administered anti-CD8β antibodies to some macaques, which 321 presumably only depleted CD8 + T cells. To describe the resulting changes in viremia, we assumed 322 that the depleting effects of anti-CD8α and anti-CD8β antibodies started at time points θ α and θ β , 323 respectively, at which points we reduced the effector populations by fractions ζ α and ζ β . Further, 324 we assumed that anti-CD8α antibodies neutralized all host effector functions, which we modelled by 325 setting m = 0 for a duration θ m representing the residence time of the depleting antibodies.
326
The procedures for solving the above model equations, parameter estimation, and data fitting are 327 described next. All the data employed for fitting was obtained by digitizing the data published in 
330
Solution of model equations 331
For ease of solution and parameter estimation, we rescaled Eqs. 1-8 in the main text using the quan-332 tities in Eqs. 9 and 10 and obtained an equivalent model with fewer parameters (Eqs. 11-18). bNAb 333 concentrations, A 1 and A 2 , and viral load, V , were not scaled because they were used for fitting data.
334
T Wherever possible, we fixed model parameter values based on previously published estimates ( Table   350 1). For instance, following Conway and Perelson 18 , we fixed the death rate of target cells, d T = 0.01 351 day -1 . We let the death rate of infected cells due to viral cytopathicity be d I = 0.5 day -1 , which is 352 ∼ 50% of the mean overall death rate of infected cells 61 , and lies at the lower end of the range of 353 the overall death rate, 0.5 − 1.7 day -1 for HIV-1 71 , with the rest attributed to effector killing. The 354 viral clearance rate was estimated 18,72 to be c = 23 day -1 for HIV-1, but has been shown to be much 355 higher (c = 38 − 302 day -1 for SIV 22, 29, 30 . We conservatively chose a value of c = 38 day -1 . To estimate 356 the effector expansion rate, k E , we obtained fits with k E adjustable, which yielded best-fit k E ∼ 0.3 357 day -1 . The model, however, had a higher value of the Akaike Information Criterion (AIC) than when k E was fixed (Table 3) . Here, we therefore chose a model with fixed k E and conservatively set k E = 0. studies that recognize underlying non-linearities 18, 19 and because smaller integral values of n did not 362 yield good fits (see below). Further, we set φ 1 = φ 2 = φ following earlier studies 19 and because fitting 363 them as separate variables yielded best-fit values that were close, φ 1 ∼ 2.1 × 10 −5 and φ 2 ∼ 5.7 × 10 −5 , 364 but with a higher AIC (Table 3) . 365 We divided the remaining parameters into two sets, ϑ = {β , m * , p * , f * , φ * , d E , ξ , V (0), Vol 1 , Vol 2 , 366 k 1 , k 2 , K} and ρ = {ω 1 , ω 2 , η 1 , η 2 }, the former assumed to follow log-normal and the latter logit-367 normal distributions, respectively. To estimate these parameters, we employed a population-based 368 fitting approach using non-linear mixed effects (NLME) models to jointly fit the log plasma viral load 369 (both treated and untreated animals) and antibody concentrations of the ten responder macaques Briefly, the parameters for all the individual macaques were assumed to be sampled from a common 375 population distribution, and the aim of the fitting exercise was to obtain estimates for the mean and 376 variance of this distribution for each parameter. For each macaque i, parameters ϑ i were estimated 377 assuming underlying log-normal distributions of the form:
where µ is the set of the population means and ψ i ∼ N(0, σ ) are normally distributed 'random effects' 379 whose variances are to be estimated. Similarly, parameters ρ i for macaque i were estimated assuming 380 underlying logit-normal distributions of the form:
where ρ min i and ρ max i are the minimum and maximum allowed values for parameters in ρ i . The latter 382 limits were set so that ω 1 , ω 2 ∈ [0, 5], and η 1 , η 2 ∈ [0.01 − 7] day -1 , expected from the 1 week dosing 383 interval employed. To account for measurement errors in observed viral loads and bNAb levels (y(t)), 384 we defined a 'combined error' model such that y(t) is normally distributed around a true value (y * (t)) 385 as described by the following equation: 386 y(t) = y * (t) + (a + b y * (t)) ψ y (t), ψ y ∼ N(0, 1)
where a is the constant error term and b is the error term proportional to the true value, y * (t).
387
All fitting except CD8 depletion was performed using Monolix software version 2019R1 (www. poor fits to viral load data, especially in phase II (green region in Figure 2 ), often with unrealistic pa-407 rameter estimates. Therefore, we first obtained parameters for each monkey from the population fits density. The scaled model equations are: 
where bNAb pharmacodynamics (A 1 and A 2 ) remain as before (Eqs. S9 and S10). Again, the model 452 could not capture the in vivo temporal viremic patterns ( Figure S7 ), reaffirming the role of the effector 453 response in establishing robust viremic control.
454
Effector proliferation rate. Lastly, we checked whether a varying effector proliferation rate (k E in Eq. 455 14) made a difference to the model fits to viral load data. The fits ( Figure S8 ) were not better than 456 those obtained with our main model by fixing k E = 0.1 day -1 (Figure 2 ), but had higher AIC (Table 3) .
457 Table 3 Summary table comparing the Akaike information criterion (AIC) of the main model with model variants. 4010 Model fits did not capture viral load data better than the main model with fixed k E = 0.1 day -1 S8 S9 limit seeding of cell-associated viral reservoirs. J Virol. 2016;90(3):1321-1332.
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